Compare ERO & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | ALVO |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Canada | Luxembourg |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | ERO | ALVO |
|---|---|---|
| Price | $25.31 | $5.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $25.00 | $9.25 |
| AVG Volume (30 Days) | ★ 1.0M | 544.6K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 696.31 | N/A |
| EPS | ★ 1.33 | 0.24 |
| Revenue | ★ $588,229,000.00 | $573,350,000.00 |
| Revenue This Year | $68.14 | $20.97 |
| Revenue Next Year | $46.45 | $43.04 |
| P/E Ratio | ★ $18.98 | $23.19 |
| Revenue Growth | 26.74 | ★ 45.55 |
| 52 Week Low | $9.30 | $4.32 |
| 52 Week High | $26.77 | $13.70 |
| Indicator | ERO | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 48.24 |
| Support Level | $23.60 | $5.23 |
| Resistance Level | $25.93 | $5.85 |
| Average True Range (ATR) | 1.14 | 0.32 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 72.48 | 80.07 |
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.